版本:
中国

最新动态: Galapagos NV (GLPG.O)

GLPG.O ( 纳斯达克 )

128.09USD
24 Jun 2019
涨跌 (%)

$0.68 (+0.53%)
收盘
$127.41
开盘
$128.64
当日最高
$128.68
当日最低
$127.96
成交量
26,150
平均成交量
112,539
52 周最高
$129.39
52 周最低
$85.00

最新动态 (Source: Significant Developments)

ProQR And Galapagos Announce Research Collaboration
2018年 1月 8日 星期一 20:00 BJT 

Jan 8 (Reuters) - Galapagos Nv ::PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY.PROQR THERAPEUTICS - UNDER AGREEMENT, TWO COMPANIES WILL WORK TOGETHER TO DISCOVER NOVEL AXIOMER EONS AGAINST FIBROSIS TARGETS SELECTED BY GALAPAGOS.PROQR THERAPEUTICS NV- TARGETS THAT WILL BE PURSUED IN COLLABORATION AND FINANCIAL DETAILS ABOUT COLLABORATION ARE NOT DISCLOSED.  全文

Galapagos NV reports Q3 loss of ‍1.75​ euro per share
2017年 10月 27日 星期五 04:01 BJT 

Oct 26 (Reuters) - Galapagos NV -:Galapagos NV qtrly ‍revenues 106.4 million euro versus 65 million euro​.Galapagos NV qtrly loss per share ‍1.75​ euro.Galapagos NV says ‍we anticipate cash burn for full year to be at lower end of guidance of euro 135 million - 155 million​.  全文

BRIEF-Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study

* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS